Alnylam Pharma (ALNY) Tops Q1 EPS by 62c, Beats on Revenue; Offers FY23 Guidance

Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.06), $0.62 better than the analyst estimate of ($1.68). Revenue for the quarter came in at $319.29 million versus the consensus estimate of $312.27 million.

For FY23 the company guided:

Combined net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO: $1,200 million – $1,285 million

Net Product Revenue Growth vs. 2022 at constant exchange rates: 34% to 44%

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Mercury Systems (MRCY) Misses Q4 EPS by 2c